Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Rhea-AI Summary
Connect Biopharma (Nasdaq:CNTB) announced that management will join a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026 at 9:30 a.m. ET.
A live webcast and a replay for about 90 days will be available in the Investors section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction – CNTB
In the May 13 session, CNTB declined 8.58%, reflecting a notable negative market reaction. Argus tracked a peak move of +9.8% during that session. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Interim trial update | Positive | -3.1% | DMC interim analysis kept Phase 2 Seabreeze STAT enrollment and design unchanged. |
| Mar 31 | Earnings and update | Neutral | +3.8% | Full-year 2025 results plus positive rademikibart data and private placement details. |
| Mar 30 | Private placement financing | Negative | -15.9% | Announced $20.2M private placement of 6,130,000 shares at $3.25 per share. |
| Mar 30 | Phase 3 AD data | Positive | -15.9% | Phase 3 RADIANT-AD showed high EASI-75 and IGA 0/1 response rates for rademikibart. |
| Mar 30 | Phase 1 IV data | Positive | -15.9% | Phase 1 IV rademikibart in asthma/COPD showed rapid, durable lung function gains. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows several positive clinical and strategic updates followed by negative or muted price reactions, while financing news aligned with a sharp selloff.
Over the past few months, CNTB reported multiple rademikibart milestones. On Mar 30, positive Phase 3 atopic dermatitis data and Phase 1 IV asthma/COPD results coincided with a $20.2M private placement, and shares fell about 15.94%. A Mar 31 full-year update with clinical progress and financing saw a modest 3.82% gain. An Apr 23 interim Phase 2 Seabreeze STAT review showed no safety issues and continued enrollment, yet the stock still declined. Today’s conference appearance fits a lighter, non-data catalyst versus those prior events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at 9:30 a.m. ET.
The live webcast of the presentation may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com. An archived replay of the event will be available on the website for approximately 90 days following the conference.
About Connect Biopharma
Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately
For more information visit www.connectbiopharma.com.
Investor Relations Contact:
Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
(212) 698-8802
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
